SCHEMBL336034

SCHEMBL336034

C1CNCCNCCCN2CCN(C1)CC2

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 11/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 1/20 0.41
HIF1A Q16665 1/20 0.40
MAPT P10636 1/20 0.40
PDE4A P27815 1/20 0.40
KDR P35968 1/20 0.40
MEN1 O00255 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
ADRA2C P18825 1/20 0.37
CCR2 P41597 1/20 0.37
CXCL12 P48061 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CHRNB2 P17787 1/20 0.30
CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9118993 0.94 CXCR4 (0.44) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL2517620 0.93 CXCR4 (0.50) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL20853809 0.90 CXCR4 (0.41) CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2
SCHEMBL336215 0.90 CXCR4 (0.41) CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2
SCHEMBL20853807 0.90 CXCR4 (0.44) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL948605 0.88 CXCR4 (0.39) CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2
SCHEMBL6861531 0.88 CXCR4 (0.39) CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2
Piperidine SCHEMBL8981286 0.87 ALDH1A1 (0.60) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
Piperazine SCHEMBL9317492 0.86 HIF1A (0.55) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL10316738 0.84 CXCR4 (0.41) CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025199636-A1 TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF MCMASTER UNIVERSITY (CA) 2025-10-02 WO claimed
EP-4556029-A2 RADIOPHARMACEUTICAL CONJUGATE The South African Nuclear Energy Corporation Limited (ZA) 2025-05-21 EP claimed
US-20250099632-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES UK LIMITED (GB) 2025-03-27 US claimed
US-20250026739-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2025-01-23 US claimed
EP-4479040-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF Full-Life Technologies HK Limited (HK) 2024-12-25 EP claimed
US-20240382630-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES UK LIMITED (GB) 2024-11-21 US claimed
US-12145926-B2 Compounds and radioligands for targeting neurotensin receptor and uses thereof FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-11-19 US claimed
EP-4436979-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF Full-Life Technologies HK Limited (HK) 2024-10-02 EP claimed
US-20240287046-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-08-29 US claimed
WO-2023158802-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF FULL-LIFE TECHNOLOGIES U.S. INC. (US) 2023-08-24 WO claimed
EP-3703676-A1 COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES Advanced Proteome Therapeutics, Inc. (US) 2020-09-09 EP claimed
US-20190175750-A1 COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES ADVANCED PROTEOME THERAPEUTICS INC. 2019-06-13 US claimed
EP-2453927-B1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES UNIV DENMARK TECH DTU (DK) 2019-05-15 EP claimed
EP-2651447-B1 ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS UNIV DENMARK TECH DTU (DK) 2018-08-29 EP claimed
US-20170296684-A1 RADIOPHARMACEUTICAL CONJUGATE UNIVERSITY OF CAPE TOWN (ZA) 2017-10-19 US claimed
US-20160158392-A1 Entrapment of Radionuclides in Nanoparticle Compositions RIGSHOSPITALET (DK) 2016-06-09 US claimed
US-9226984-B2 Entrapment of radionuclides in nanoparticle compositions Technical University of Denmark and Rigshospitalet (DK) 2016-01-05 US claimed
US-8920775-B2 Loading technique for preparing radionuclide containing nanoparticles TECHNICAL UNIVERSITY OF DENMARK (DK) 2014-12-30 US claimed
US-20130251630-A1 Entrapment of Radionuclides in Nanoparticle Compositions RIGSHOSPITALET (DK) 2013-09-26 US claimed
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES RIGSHOSPITALET (DK) 2012-08-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026739-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF NTSR1, NTSR2, NPSR1 CXCR4 447/4885SMN1; SMN2 1239/4885ALDH1A1 3833/4885
US-20240382630-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF ASGR1, GNRHR, SCTR CXCR4 641/4885SMN1; SMN2 3813/4885ALDH1A1 3790/4885
US-20240287046-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF NTSR1, NTSR2, NPSR1 CXCR4 456/4885SMN1; SMN2 1182/4885ALDH1A1 3641/4885
US-20250099632-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF ASGR1, GNRHR, SCTR CXCR4 641/4885SMN1; SMN2 3813/4885ALDH1A1 3790/4885
US-12145926-B2 Compounds and radioligands for targeting neurotensin receptor and uses thereof NTSR1, NTSR2, NPSR1 CXCR4 456/4885SMN1; SMN2 1182/4885ALDH1A1 3641/4885
US-20190175750-A1 COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES PTMS, SRMS, ACP1 CXCR4 1899/4885SMN1; SMN2 2132/4885ALDH1A1 3789/4885
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES LIPG, NPC1L1, CD47 CXCR4 790/4885SMN1; SMN2 4425/4885ALDH1A1 4468/4885
US-20170296684-A1 RADIOPHARMACEUTICAL CONJUGATE FOLH1, EPRS1, FOLR1 CXCR4 571/4885SMN1; SMN2 2999/4885ALDH1A1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.